Marine fish oil supplements are frequently administered with other lipid medications for treatment of hypertriglyceridemia. The efficacy of fish oil may be reduced in the presence of other lipid agents, particularly fibrates that also act as PPARα agonists. We therefore sought to determine the efficacy of fish-oil supplements when coadministered with other lipid-modifying agents.
Patients receiving fish oil supplements were identified from the computer database of a large governmental HMO. Change in plasma lipoprotein levels after administration of fish oil was compared between patients receiving fish oil as their only treatment and those for whom fish oil was added to other drugs.
A total of 166 evaluable records were identified, 66 from patients treated with fish oil alone and 100 from patients for whom fish oil was added to another agent or other agents. Fish oil effectively reduced triglyceride levels to an equal extent in the fish oil only and fish oil added groups (−30% versus –27% respectively; P=0.84).
Fish oil effectively reduces plasma triglyceride levels when administered with concomitant lipid medications. These findings suggest the presence of additional and even complementary mechanisms of action of fish oil to lower triglyceride when added to other lipid drugs. These findings validate the common clinical practice of combining fish oil supplements with other lipid-lowering medications in patients with hypertriglyceridemia.
KEY INDEXING TERMS
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of the Medical Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione.Circulation. 2002; 105: 1874-1875
- Omega-3 fatty acids from fish oils and cardiovascular disease.Mol Cell Biochem. 2004; 263: 217-225
- Hypolipidemic effects of n-3 fatty acids in primary hyperlipoproteinaemia.J Intern Med Suppl. 1989; 731: 91-97
- Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia.Clin Investig. 1993; 71: 314-318
- Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study.Horm Metab Res. 1996; 28: 230-236
- Mechanism of action of fibrates on lipid and lipoprotein metabolism.Circulation. 1998; 98: 2088-2093
- Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia.Am J Cardiol. 1997; 80: 797-798
- A chemical switch regulates fibrate specificity for peroxisome-proliferator-activated receptor (PPAR) vs. liver X receptor (LXR).J Biol Chem. 2003; : 2403
- Multiple mechanisms for polyunsaturated fatty acid regulation of hepatic gene transcription.Prostaglandins Leukot Essent Fatty Acids. 1999; 60: 345-349
- Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil.J Biol Chem. 2001; 276: 4634-4639
- SREBP-1c expression is suppressed by dietary polyunsaturated fatty acids.J of Biol Chem. 1999; 274: 23577-23583
- Dietary olive oil and menhaden oil mitigate induction of lipogenesis in hyperinsulinemic corpulent JCR:LA-cp rats: microarray analysis of lipid-related gene expression.Endocrinology. 2004; 145: 5847-5861
- Safety and efficacy of Omacor in severe hypertriglyceridemia.J Cardiovasc Risk. 1997; 4: 385-391
Accepted: November 6, 2006
Received: August 1, 2006
This work was supported in part by the Medical Research Service of the Department of Veterans Affairs.
© 2007 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.